Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC

Saved in:
Bibliographic Details
Published inAnnals of Oncology Vol. 29; pp. viii545 - viii546
Main Authors T. Goldberg, David Planchard, J. McGill, Pasi A. Jänne, X. Gu, Helena Alexandra Yu, Denis Moro-Sibilot, J. Li, C. Yu, E. Slosberg
Format Journal Article
LanguageJapanese
Published Elsevier BV 01.10.2018
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1093/annonc/mdy292.127